CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

SlMYB32 was identified as a repressor regulating phenylpropanoid pathway. CRISPR/Cas9-mediated mutagenesis of SlMYB32 results ...

A group of researchers developed a promising fix to CRISPR-Cas9's problem with unwanted genetic changes using a method that allows them to turn off gene-editing until it reaches key cell cycle phases ...

A biotech company is looking to get approval next after their recent discovery.

Last year a ten-month old baby in the US was the first person in the world to have their rare genetic disease effectively cured through the use of CRISPR gene editing technology. But the roll out of ...

CRISPR functions as a programmable genetic memory system derived from bacterial immune defenses against viral infections. Guide RNA allows for rapid multiplexed targeting compared to older ...

In May 2025, the world celebrated the success of KJ, an infant who was treated with the world’s first personalized CRISPR gene editing therapy. KJ was born with severe carbamoyl phosphate synthetase 1 ...

A novel CRISPR-based technology can spread within bacterial populations to eliminate antibiotic resistance. In a potential breakthrough for tackling antibiotic resistance, researchers from the ...